• Explore /
  • Poster
  • / Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early‑stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.

Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early‑stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.

Abstract Poster

Authors

null

Bent Ejlertsen

Department of Oncology, Rigshospitalet, Copenhagen, Denmark

Bent Ejlertsen , Carlos H. Barrios , Erhan Gokmen , Nicholas Robert , Noelia Martinez , John S. Link , Serafin Morales , Manuel Ruiz Borrego , Manish Bhandari , Yoshiaki Rai , Adam Luczak , Takashi Fujita , Alvin Wong , Bin Yao , Miguel Martin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT00878709

Citation

J Clin Oncol 36, 2018 (suppl; abstr 549)

DOI

10.1200/JCO.2018.36.15_suppl.549

Abstract #

549

Poster Bd #

41

Abstract Disclosures

Similar Posters

First Author: Arlene Chan

First Author: Michael Gnant

First Author: Beverly Moy

First Author: Gavin M. Marx